1. Home
  2. HQI vs LYEL Comparison

HQI vs LYEL Comparison

Compare HQI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

SELL

Current Price

$17.73

Market Cap

232.1M

ML Signal

SELL

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$15.43

Market Cap

195.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQI
LYEL
Founded
2002
2018
Country
United States
United States
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.1M
195.8M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
HQI
LYEL
Price
$17.73
$15.43
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$19.00
★ $37.88
AVG Volume (30 Days)
25.4K
★ 145.2K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
★ 1.44%
N/A
EPS Growth
★ 73.08
N/A
EPS
★ 0.31
N/A
Revenue
★ $30,640,000.00
$36,000.00
Revenue This Year
$0.54
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$53.68
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.38
$7.20
52 Week High
$20.84
$45.00

Technical Indicators

Market Signals
Indicator
HQI
LYEL
Relative Strength Index (RSI) 45.91 58.08
Support Level $15.28 $7.20
Resistance Level $18.49 $15.38
Average True Range (ATR) 0.98 0.78
MACD -0.09 0.36
Stochastic Oscillator 34.17 77.78

Price Performance

Historical Comparison
HQI
LYEL

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: